Cargando…

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS

Detalles Bibliográficos
Autores principales:	Sartor, Chiara, Ottaviani, Emanuela, Nanni, Jacopo, Ciruolo, Raffaele, Cristiano, Gianluca, Zannoni, Letizia, Zingarelli, Federico, Bandini, Lorenza, Patuelli, Agnese, Venturi, Claudia, Robustellu, Valentina, Forte, Dorian, Cavo, Michele, Curti, Antonio, Papayannidis, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430060/ http://dx.doi.org/10.1097/01.HS9.0000974296.37939.40

Ejemplares similares

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia
por: De Cicco, Marica, et al.
Publicado: (2023)

PB1880: ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 – A DIFFERENT ENTITY IN THE ELDERLY?
por: Gomes, Rita S, et al.
Publicado: (2023)

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
por: Marconi, Giovanni, et al.
Publicado: (2023)

PB1775: DEVELOPMENT OF ASSAY CALIBRATION MEHTHODOLOGY FOR CEPHEID XPERT® NPM1 MUTATION PROTOTYPE ASSAY
por: Liu, Y., et al.
Publicado: (2022)

PB1792: NGS VS PCR FOR THE DETECTION OF NPM1 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA.
por: Severina, N., et al.
Publicado: (2022)

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY
por: Fathi, A., et al.
Publicado: (2022)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

AKT regulates NPM dependent ARF localization and p53(mut) stability in tumors
por: Hamilton, Garth, et al.
Publicado: (2014)

PB1894: NPM1 MUTATED ACUTE MYELOID LEUKEMIA: THE CO-MUTATION PATTERNS MAY BE ASSOCIATED WITH PROGNOSIS
por: Varelas, Christos, et al.
Publicado: (2023)

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
por: Amato, Viviana, et al.
Publicado: (2023)

PB1797: THE PROGNOSTIC SIGNIFICANCE OF BCAT1 ON NPM1+FLT3-ITD+ AML PATIENTS AND RELATED MOLECULAR MECHANISMS
por: Pan, Xinan, et al.
Publicado: (2023)

PB1867: ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 – REAL-LIFE EXPERIENCE IN THE REDEFINITION OF EUROPEAN LEUKEMIANET RISK CLASSIFICATION
por: Gomes, Rita S, et al.
Publicado: (2023)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
por: Kayser, Sabine, et al.
Publicado: (2023)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
por: Patel, Anand, et al.
Publicado: (2023)

PB1759: RETAINED FUNCTIONAL NORMAL AND/OR PRE-LEUKEMIC HSCS IN THE BONE MARROW ARE ASSOCIATED TO GOOD PROGNOSIS IN DNMT3AMUTNPM1MUT AML PATIENTS
por: Donato, Elisa, et al.
Publicado: (2023)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS
por: Ocadlikova, Darina, et al.
Publicado: (2023)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

A Case Report of Acute Myeloid Leukemia and Neurofibromatosis 1
por: Sartor, Chiara, et al.
Publicado: (2013)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

The value of molecular stratification for CEBPA (DM) and NPM1 (MUT) FLT3 (WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015)

MutS/MutL crystal structure reveals that the MutS sliding clamp loads MutL onto DNA
por: Groothuizen, Flora S, et al.
Publicado: (2015)

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
por: Simonetti, Giorgia, et al.
Publicado: (2021)

The Harveian Oration, 1865
Publicado: (1866)

Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
por: Khan, I., et al.
Publicado: (2023)

The Presence of the DNA Repair Genes mutM, mutY, mutL, and mutS is Related to Proteome Size in Bacterial Genomes
por: Garcia-Gonzalez, Aurian, et al.
Publicado: (2012)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uobp43puvrbvtbpsmfa0nhhkcb